Implications of pharmacogenomics for drug development and clinical practice.

作者: Geoffrey S Ginsburg , Richard P Konstance , Jennifer S Allsbrook , Kevin A Schulman

DOI: 10.1001/ARCHINTE.165.20.2331

关键词:

摘要: Pharmacogenomics is likely to be among the first clinical applications of Human Genome Project and certain have an enormous impact on practice medicine. Herein, we discuss potential implications pharmacogenomics drug development process, including safety, productivity, market segmentation, expansion, differentiation, personalized health care. We also review 3 challenges facing translation into practice: dependence information technology, limited care financing, scientific uncertainty surrounding validation specific technology. To our knowledge, there currently no formal agenda promote cultivate innovation, develop progressive or obtain financing that would required advance use pharmacogenomic technologies in patient Although these driving change sciences, it remains seen which systems level needs will addressed.

参考文章(47)
Anne S. Tsao, Hagop Kantarjian, Moshe Talpaz, STI-571 in chronic myelogenous leukaemia. British Journal of Haematology. ,vol. 119, pp. 15- 24 ,(2002) , 10.1046/J.1365-2141.2002.03899.X
Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
Sarah K Tate, David B Goldstein, Will tomorrow's medicines work for everyone? Nature Genetics. ,vol. 36, ,(2004) , 10.1038/NG1437
Richard V. McCloskey, Treatment of Septic Shock with Human Monoclonal Antibody HA-1A Annals of Internal Medicine. ,vol. 121, pp. 1- 5 ,(1994) , 10.7326/0003-4819-121-1-199407010-00001
Elizabeth Mansfield, Timothy J. O'Leary, Steven I. Gutman, Food and Drug Administration Regulation of in Vitro Diagnostic Devices The Journal of Molecular Diagnostics. ,vol. 7, pp. 2- 7 ,(2005) , 10.1016/S1525-1578(10)60002-5
Arno G. Motulsky, DRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICS Journal of the American Medical Association. ,vol. 165, pp. 835- 837 ,(1957) , 10.1001/JAMA.1957.72980250010016
David G. Savage, Karen H. Antman, Imatinib Mesylate — A New Oral Targeted Therapy The New England Journal of Medicine. ,vol. 346, pp. 683- 693 ,(2002) , 10.1056/NEJMRA013339